Peptide Schedule
Octreotide (Sandostatin)8 residuesFCYWKTCTEach bubble = one amino acid. Size = residue mass. Color = chemical class.Octreotide (Sandostatin) Dosage Calculator
Octreotide is a synthetic octapeptide analog of natural somatostatin, first approved by the FDA in 1988 for the treatment of acromegaly.
50mcg · 3x Daily
Summary: Add 0mL BAC water to your 0.05mg vial. Draw to < 0.1 units on a U-100 syringe for a 50mcg dose. This vial will last 0 doses.
Cycle Planner
Octreotide (Sandostatin) Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = ~1.7-1.9 hours (subcutaneous)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Octreotide (Sandostatin) Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 50mcg | 3x Daily |
| Moderate | 100mcg | 3x Daily |
| Aggressive | 200mcg | 3x Daily |
Note: Octreotide is an FDA-approved synthetic somatostatin analog available in two formulations: Sandostatin (short-acting subcutaneous injection, dosed 2-3 times daily) and Sandostatin LAR Depot (long-acting intramuscular injection, dosed every 28 days at 10-30 mg). Supplied as a pre-filled solution — no reconstitution with bacteriostatic water is needed. Dosing in the calculator reflects subcutaneous Sandostatin Injection in mcg. For the LAR depot formulation, doses range from 10-30 mg IM every 4 weeks and must be administered by a healthcare provider. Dose adjustments are needed in patients with hepatic cirrhosis. This is a prescription medication and should only be used under medical supervision.
About Octreotide (Sandostatin)
Octreotide is a synthetic octapeptide analog of natural somatostatin, first approved by the FDA in 1988 for the treatment of acromegaly. It mimics the hormone somatostatin but with a dramatically longer half-life — about 1.7 to 1.9 hours compared to 1-3 minutes for native somatostatin — making it practical for clinical use. The drug works primarily by binding to somatostatin receptor subtypes 2 and 5 (SST2 and SST5), suppressing the release of growth hormone, insulin, glucagon, and multiple gastrointestinal hormones. Octreotide carries three FDA-approved indications: acromegaly (reducing growth hormone and IGF-1 levels when surgery or radiation hasn't achieved adequate control), carcinoid syndrome (managing severe diarrhea and flushing episodes from metastatic carcinoid tumors), and VIPomas (controlling profuse watery diarrhea caused by vasoactive intestinal peptide-secreting tumors). The landmark PROMID trial also demonstrated its antiproliferative effects in neuroendocrine tumors, and it's now approved in over 40 countries for tumor growth control in well-differentiated midgut NETs. Two formulations are available: Sandostatin Injection for subcutaneous or IV use (dosed 2-3 times daily), and Sandostatin LAR Depot for monthly intramuscular injection. The short-acting form offers near-complete bioavailability (~100% SC) with peak plasma levels at about 0.4 hours. The LAR formulation uses microsphere technology to release octreotide gradually over 4 weeks, with ~60% bioavailability relative to the SC form. While generally well tolerated, the most common limitation is gallstone formation — occurring in 25-65% of long-term users — due to the drug's suppression of gallbladder contractility and bile secretion. Blood glucose abnormalities (both hyper- and hypoglycemia) also require monitoring, as octreotide suppresses both insulin and glucagon. Octreotide has been in clinical use for over 35 years with an extensive safety and efficacy database.